Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study
Datum
2016Language
en
Schlagwort
Zusammenfassung
Background: G209A SNCA mutation carriers represent an important group of genetic PD. We describe motor and nonmotor features of G209A SNCA mutation carriers. Methods: Longitudinal clinical assessments over 2 years were collected in 22 symptomatic and 8 asymptomatic G209A SNCA mutation carriers. Motor and nonmotor rating scales were administered. Correlations were performed between clinical variables and disease duration or age. Penetrance was calculated using Kaplan-Meier survival curves. Results: Asymptomatic carriers did not manifest clear premotor symptoms, but symptomatic carriers often reported that olfactory dysfunction and rapid eye movement sleep behavior disorder preceded motor symptoms. Prominent motor decline and deterioration of autonomic and cognitive function occurred at follow-up; such nonmotor features correlated with disease duration, but not age. Disease penetrance was estimated at around 90%. Conclusions: This study may help to inform clinical trials and provide the basis for studies of disease modifiers in genetic synucleinopathy cohorts. © 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Christodoulou C., Kalogera-Fountzila A., Karavasilis V., Kouvatseas G., Papandreou C.N., Samantas E., Varaki K., Papadopoulos G., Bobos M., Rallis G., Razis E., Goudopoulou A., Kalogeras K.T., Syrigos K.N., Fountzilas G. (2017)Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing ... -
A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease
Giagkou N., Maraki M.I., Yannakoulia M., Kosmidis M.H., Dardiotis E., Hadjigeorgiou G.M., Sakka P., Ntanasi E., Anastasiou C.A., Xiromerisiou G., Stefanis L., Scarmeas N., Stamelou M. (2020)Objective: The objective of this study was to validate the recently updated research criteria for prodromal Parkinson's disease (pPD) proposed by the International Parkinson's Disease and Movement Disorders Society. Methods: ... -
Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece
Kyriakopoulos C., Gogali A., Exarchos K., Potonos D., Tatsis K., Apollonatou V., Loukides S., Papiris S., Sigala I., Katsaounou P., Aggelidis M., Fouka E., Porpodis K., Kontakiotis T., Sampsonas F., Karampitsakos T., Tzouvelekis A., Bibaki E., Karagiannis K., Antoniou K., Tzanakis N., Dimeas I., Daniil Z., Gourgoulianis K., Kouratzi M., Steiropoulos P., Antonakis E., Papanikolaou I.C., Ntritsos G., Kostikas K. (2021)Introduction: During the first COVID-19 wave, a considerable decline in hospital admissions was observed worldwide. Aim: This retrospective cohort study aimed to assess if there were any changes in the number of patients ...